The NPM-MLF1 chimeric protein is produced by the t(3;5)(q25.1;q34) chromosomal translocation, which is associated with myelodysplastic syndrome (MDS) prior to progression into acute myeloid leukemia (AML). Here we report that K562 human leukemia cells ectopically expressing NPM-MLF1, but not those with wild-type MLF1, were gradually eliminated from the culture by undergoing apoptosis. NIH3T3 mouse ®broblasts engineered to overexpress NPM-MLF1 grew normally but serum deprivation triggered apoptotic cell death with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1. Quantitative analysis of apoptotic induction con®rmed that, neither NPM nor MLF1, but the NPM-MLF1 fusion protein was able to induce apoptosis. Analyses using a variety of deletion mutants of NPM-MLF1 revealed that induction of apoptosis required the N-terminal domain of MLF1 and the NPM domain containing nuclear localization signal and that removal of the NPM dimerization domain markedly impaired the ability to induce apoptosis. Co-expression of Bcl-2 rescued NIH3T3 ®broblasts from NPM-MLF1-mediated cell death without aecting the expression level or the subcellular localization of NPM-MLF1 and enabled cells to progress into S phase in low serum. These ®ndings provide an NPM-MLF1-mediated novel mechanism of apoptotic induction and imply that NPM-MLF1 in collaboration with anti-apoptotic oncoproteins may play an important role in multi-step progression from MDS to AML.
Introduction
Myelodysplastic syndromes (MDSs) are a group of stem cell disorders characterized by ineective hematopoiesis with trilineage dysplasia and often correlated with transformation into acute myeloid leukemia (AML) (Bennett et al., 1982; Koeer, 1986) . MDS patients have peripheral cytopenias despite frequently having normo-or hypercellular bone marrows (BMs). One possible explanation for this apparent paradox is that although there are a large number of cells in the BM, they undergo apoptotic cell death before terminal dierentiation (Clark and Lampert, 1990; Yoshida, 1993; Raza et al., 1995) . Massive apoptosis, however, has not been observed in BM cells from MDS patients. This could partly be that apoptotic cells are rapidly engulfed by adjacent marrow cells. In fact, an increased number of phagocytosis of apoptotic cells in MDS has been reported (Clark and Lampert, 1990; Koeer, 1986) . Alternatively, apoptosis in MDS may occur with much slower kinetics than in any other physiological situations. Therefore, conventional methods to detect apoptosis such as morphological identi®cation, detection of DNA laddering by gel electrophoresis, and a terminal-deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) assay, may not be suitable to detect apoptosis in MDS because they all recognize the late stages of apoptosis.
MDSs are clonal disorders involving one or more clones, suggesting that certain genetic aberrations occurred in relatively immature progenitors are responsible for MDS. The potential involvement of ras, IRF-1 and p53 has been suggested by their frequent mutations or deletions in MDS (Fenaux et al., 1996; Gallagher et al., 1997; Koeer, 1996; Paquette et al., 1993; Wattel et al., 1994; Willman et al., 1993) . However, the precise molecular mechanisms responsible for ineective hematopoiesis presumably by excessive apoptosis (Clark and Lampert, 1990; McKenna and Cotter, 1997; Raza et al., 1995; Thompson, 1995; Yoshida, 1993) and transformation into leukemia are largely unknown. One diculty with molecular analyses of MDS is that the loss of chromosomal material such as del 5q, del 20q, del 11q, or del 7q is the major cytogenetic abnormality found in MDS (Koeer, 1996; Fenaux et al., 1996; Gallagher et al., 1997) . During the last decade, however, analyses of the abnormal proteins derived from chromosomal translocations have provided crucial insights into the molecular mechanisms of tumorigenesis in a variety of leukemias and lymphomas (Rabbitts, 1994; Look, 1997) . It has been reported that the t(3;5)(q25.1;q34) chromosomal translocation is restricted to MDS and AML except for acute promyelocytic leukemia (Raimondi et al., 1989) , and this suggests that the resultant fusion protein (NPM-MLF1) consisting of nucleophosmin (NPM) (SchmidtZachmann and Franke, 1988; Chan et al., 1989) and a novel cytoplasmic protein, myelodysplasia/myeloid leukemia factor 1 (MLF1) (Yoneda-Kato et al., 1996) , is involved in dysregulation of pluripotent progenitor cells and plays a role in ineective hematopoiesis and/or multi-step transformation into overt leukemia.
NPM is a highly conserved nonribosomal RNAbinding nucleolar phosphoprotein, one of which function is a shuttle protein, transporting ribosomal ribonucleoproteins (rRNPs) between the nucleolus and the cytoplasm during the assembly of ribosomes (Schmidt-Zachmann et al., 1987; Borer et al., 1989) . NPM forms a hexameric homo-oligomer (assembled in a head-to-head/tail-to-tail fashion) as it shuttles between subcellular compartments (Yung and Chan, 1987; Schmidt-Zachmann and Franke, 1988; Liu and Chan, 1991) . NPM is involved in two other chromosomal translocations, t(2;5) and t(5;17), which produce chimeric proteins NPM-ALK and NPMRARa, respectively (Morris et al., 1994; Redner et al., 1996) . The region of NPM retained in the NPM-MLF1 fusion protein contains most of the identi®able functional domains of NPM, including a potential Cys-X 5 -His-X 4 -His metal binding motif, one of two nuclear localization signals (NLSs), and most of the acidic amino acid clusters (Yoneda-Kato et al., 1996) , while NPM-ALK and NPM-RARa contain 58 less NPMderived amino acids (Morris et al., 1994; Redner et al., 1996) , suggesting that functional modi®cation of MLF1 by fusion to NPM is dierent from that for ALK and RARa. All three fusion proteins, however, retain the N-terminal domain of NPM, which are required for dimerization of the protein (Fujimoto et al., 1996; Bischof et al., 1997) . The ALK and RARa genes encode a tyrosine kinase and a transcription factor, respectively, whereas the function of MLF1 remains unknown because of no signi®cant homology with any previously identi®ed proteins, suggesting that NPM-MLF1 acts through a novel pathway to contribute to myeloid neoplasia.
In this study, we examined the eect of ectopic expression of NPM-MLF1 fusion proteins in K562 human leukemia cells and in NIH3T3 mouse fibroblasts. We found that ectopic NPM-MLF1 expression induced apoptotic cell death with slow kinetics in proliferating K562 cells and in serum-starved NIH3T3 cells. NPM-MLF1-mediated apoptosis required the Nterminal domain of MLF1, and dimerization and nuclear transportation of the protein. Co-expression of Bcl-2 rescued cells from NPM-MLF1-mediated cell death and enabled them to progress into S phase in low serum, implying that sequential activation of NPM-MLF1 and anti-apoptotic proto-oncogenes could collaboratively contribute to malignant transformation.
Results
To examine the eect of the NPM-MLF1 fusion protein on non-lymphoid hematopoietic cells, human K562 erythroleukemia cells, which express low levels of endogenous wild-type MLF1 protein (Yoneda-Kato et al., 1996) , were electroporated with a control expression vector containing a neo gene conferring resistance to G418 or with vectors encoding NPM-MLF1 or wild-type MLF1. Electroporated cells were selected in G418 for 2 weeks and the ectopic expression of each protein was analysed by immunoprecipitation followed by Western blotting using antibody which speci®cally recognizes the C-terminus of MLF1 (Yoneda-Kato et al., 1996) . Both NPM-MLF1 and MLF1 proteins were detected in cells 3 days after electroporation as well as in cells after 2 weeks of G418 selection ( Figure 1a , Early Passage). However, NPM-MLF1 proteins were undetectable after 2 months post-G418 selection, while the relatively high levels of wild-type MLF1 proteins were sustained (Figure 1a , Late Passage). The growth of`Early Passage' cells expressing NPM-MLF1 proteins was signi®cantly slower (doubling time; c. 44 h) than that of cells introduced with an empty vector or the MLF1 vector (both doubling times; c. 28 h) (Figure 1b) . After 2 months post-G418 selection, no signi®cant dierence was observed among the growth rates of the three transfectants (data not shown). These observations indicate that K562 cells expressing NPM-MLF1 proteins had growth disadvantage and were gradually eliminated from the culture.
A substantial number of dead cells were detected by a trypan blue exclusion assay in`Early Passage' NPM-MLF1 transfectants but not in cultures transfected with an empty or the MLF1 vector. The dying cells iǹ Early Passage' NPM-MLF1 culture exhibited nuclear fragmentation and chromatin condensation and were positive in a TUNEL assay (Figure 1c ). Furthermore, DNAs isolated from`Early Passage' NPM-MLF1 transfectants displayed the ladder pattern commonly generated in the later stages of apoptosis (Figure 1d ), while neither`Late Passage' cultures nor MLF1 and empty vector transfectants did so at any stage. Thus, K562 cells ectopically expressing NPM-MLF1 were induced to die by undergoing apoptosis.
NPM-MLF1-mediated apoptosis was observed in other erythroleukemia cell lines such as HEL cells, which express low levels of endogenous wild-type MLF1 protein. However, when interleukin-3 (IL-3)-dependent 32D mouse immature myeloid cells were introduced with a NPM-MLF1 vector, the transfected cells (32D/NPM-MLF1 cells) expressed the level of fusion proteins much higher than that of K562`Early Passage' NPM-MLF1-transfectants and stably maintained the high NPM-MLF1 protein levels for more than 3 months (negative data, not shown). 32D/NPM-MLF1 cells normally grew in the presence of IL-3 with a doubling time (c. 16 h) equivalent to that of parental 32D cells. Withdrawal of IL-3 from the medium induced apoptosis in parental 32D cells and ectopic overexpression of the fusion protein did not accelerate the kinetics of apoptotic induction. In addition, 32D/ NPM-MLF1 cells responded to granulocyte colonystimulating factor (G-CSF) as eectively as parental cells. These results argue against the idea that overexpression of NPM-MLF1 fusion proteins simply increases the non-speci®c stress of the cells to induce apoptosis. Taking it into consideration that 32D cells expressed undetectable levels of mouse MLF1 mRNA or proteins, it is possible that these cells do not express eector molecules functioning downstream of both NPM-MLF1 and MLF1. Thus, induction of NPM-MLF1-mediated apoptosis is a quite speci®c phenomenon and might require the signaling pathway involving wild-type MLF1.
Mouse NIH3T3 ®broblasts engineered to overexpress NPM-MLF1 grew normally ( Figure 2a top and middle panels). They were contact-inhibited and anchorage-dependent, and their overall growth rate was not signi®cantly dierent from that of parental cells. Expression levels of NPM-MLF1 proteins in nucleus remained the same even 6 months after transfection. However, after transfer into medium containing 0.1% serum, a considerable fraction of cells transfected with NPM-MLF1, but not MLF1 or an empty vector, exhibited round morphology and did not attach to a solid support (Figure 2a bottom panel) . TUNEL analysis demonstrated that these cells showed the mass DNA breakage characteristic of apoptosis. After removal of¯oating cells,¯at cells remaining on the plate did not express NPM-MLF1 proteins. Aequorea green¯uorescent protein (GFP) (Ogawa et al., 1995) was used as a transfection marker to comparatively analyse the kinetics of apoptosis induced by ectopic overexpression of NPM-MLF1, cMyc or E2F-1 (Evan et al., 1992; Askew et al., 1991; Wu and Levine, 1994; Qin et al., 1994; Shan and Lee, 1994) followed by serum starvation. Figure 2b shows that NPM-MLF1 transfectants died gradually during 72 h after serum starvation, while most of the c-Myc and E2F-1 transfectants rapidly lost their viability within 24 h. These observations indicate that ectopic overexpression of NPM-MLF1 in mouse ®broblasts induced apoptotic cell death upon serum deprivation with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1.
Deletion mutants of NPM-MLF1 were constructed to analyse the functional domains of the fusion protein ( Figure 3a) . All mutants were tagged by a hemagglutinin (HA) epitope at their N-terminal ends and inserted into the expression vector. Full-length NPM-MLF1 and wild-type MLF1 were tagged by an HAepitope and NPM was fused with a FLAG tag. In transiently transfected Cos7 cells, the mutant constructs expressed proteins with expected molecular weights at almost equal levels (Figure 3b ). To analyse subcellular localization of the mutants, each of the expression vectors were transfected into NIH3T3 cells and stained with anti-HA or anti-FLAG antibody (Figure 4) . MLF1 was mostly found in the cytoplasm, whereas NPM was detected in the nucleus, with highest levels in the nucleolus. NPM-MLF1 was localized to the nucleus/nucleolus, consistent with the results previously published (Yoneda-Kato et al., 1996) . The deletion mutants lacking amino acid residues 84 ± 192 (NPM-MLF1/193 ± 427 and NPM-MLF1/Del 84 ± 192) were detected in the cytoplasm, while other mutants were found in the nucleus. This region contains several identi®able functional domains of NPM (Figure 3a ) such as a potential Cys-X 5 -His-X 4 -His metal binding motif (MB), one of two nuclear localization signals (N), and most of the glutamic and aspartic acid residues present in the two acidic amino acid clusters (AC), among which nuclear localization signal sequence seems to be most responsible for the nuclear targeting, but possible contribution of the other domains is not excluded at the present moment.
To determine the domains essential for apoptotic induction, the expression vectors were introduced into NIH3T3 cells together with the GFP plasmid and were tested for their ability to induce cell death after serum deprivation (Figure 3c ). Transfected cells expressed almost equal levels of mutant proteins, as was examined by immunoblotting using anti-HA antibody (data not shown). Approximately 90% of cells expressing full-length NPM-MLF1 underwent apoptotic cell death as judged by typical round morphology, a trypan blue exclusion assay, and TUNEL analysis, while those with an empty vector and those expressing NPM or MLF1 survived (c. 80%). Among C-terminus deletion mutants, two mutants missing either 39 Cterminal amino acids (NPM-MLF1/1 ± 388) or 143 Cterminal amino acids (NPM-MLF1/1 ± 284) induced apoptosis with the same frequency and similar kinetics as full-length NPM-MLF1 proteins, whereas a mutant consisting of the NPM domain and only 16 amino acids of MLF1 sequences (NPM-MLF1/1 ± 192) failed to do so, suggesting that amino acid residues 193 ± 284 contain a domain required for the fusion protein to induce apoptosis. In fact, cells expressing a mutant lacking this domain (NPM-MLF/Del 193 ± 284) did not undergo apoptosis. Mutants missing all or Cterminal half of the NPM domain (NPM-MLF1/193 ± 427 and NPM-MLF1/Del 84 ± 192, respectively) basically behaved in a way similar to wild-type MLF1 in terms of cytoplasmic localization and failure to induce apoptosis. The expression levels of NPM-MLF1/ Del 84 ± 192 appeared to be slightly lower in Cos7 cells than those of other mutants (Figure 3b ) but were quite the same in NIH3T3 cells (we con®rmed this by immuno¯uorescent staining followed by quantitative analysis using confocal microscopy as well as by immunoblotting), indicating that inability of apoptotic induction was not due to the lower expression but to the loss of part of the NPM domain. Deletion of Nterminal 83 amino acids (NPM-MLF1/84 ± 427), which are required for dimerization of NPM, markedly reduced but did not completely eliminate the apoptosis-inducing activity. Identical results were obtained when the mutants were assayed in K562 cells (data not shown). Thus, NPM-MLF1 contains at least three functional domains: (1) the middle portion of the fusion protein corresponding to the N-terminal half of MLF1 (amino acids 193 ± 284); (2) C-terminal half of the NPM domain (amino acids 84 ± 192) containing several functional motifs, among which nuclear localization signal sequence seems to be most important; and (3) N-terminal 83 amino acids containing a domain required for dimerization of the protein.
(1) and (2) were essential for apoptotic induction and (3) enhances the activity.
To gain further insight into the action of the NPM-MLF1 fusion protein, we examined whether an antiapoptotic proto-oncogene, Bcl-2 (Hockenbery et al., Korsmeyer, 1996) , abrogates the cell death induced by NPM-MLF1. GFP-positive NIH3T3 cells transfected with the NPM-MLF1 plasmid together with the human Bcl-2 expression vector exhibited a normal morphology even 5 days after transfer into medium containing 0.1% serum (Figure 5a second row). More than 80% of NPM-MLF1 transfectants died of apoptosis, while approximately 90% of cells expressing both NPM-MLF1 and Bcl-2 survived under these conditions (Figure 5b ). Exogenous Bcl-2 did not reduce the level of NPM-MLF1 expression (Figure 5c ) and nuclear expression of NPM-MLF1 was readily detected even after serum deprivation (Figure 5a third row). In medium containing 0.1% serum, less than 5% of parental NIH3T3 cells incorporated BrdU, indicating that normal ®broblasts were unable to proliferate in low serum. However, more than 80% of cells coexpressing NPM-MLF1 and Bcl-2 incorporated BrdU in medium containing 0.1% serum (Figure 5a fourth row and d), while less than 5% of cells transfected with an empty vector or Bcl-2 alone did so under these conditions (Figure 5a bottom row and d) . Taken together, co-expression of Bcl-2 with NPM-MLF1 not only rescued serum-starved ®broblasts from apoptotic cell death but gave them the growth advantage to proliferate under conditions where normal cells were completely growth arrested. The fact that cells overexpressing Bcl-2 alone did not enter S phase in low serum indicates that the NPM-MLF1 fusion proteins play an important role in promotion of cell proliferation. However, additional molecular abnormalities seem to be required for neoplastic transformation because cells expressing both NPM-MLF1 and Bcl-2 exhibited normal morphology and were still contactinhibited and anchorage-dependent.
Discussion
Certain oncoproteins are known to induce apoptotic cell death in any types of cells introduced with their expression vectors. Ectopic expression of the NPM-MLF1 fusion protein induced apoptosis in human erythroleukemia cell lines such as K562 and HEL cells, but the fact that it failed to do so in IL-3-dependent mouse 32D myeloid cells, which are not necessarily refractory to apoptosis, strongly suggests that NPM-MLF1 activates a speci®c signaling pathway that ultimately leads to apoptosis rather than that it induces apoptosis by increasing non-speci®c intracellular stresses. NPM-MLF1 induced apoptosis in serumstarved mouse NIH3T3 ®broblasts, implying that human fusion proteins can functionally interact with mouse molecules that mediate signals. It is conceivable that 32D cells do not express eector molecules that function downstream of NPM-MLF1 because they express undetectable levels of MLF1 and may not need MLF1-mediated signaling pathways for their survival, proliferation, and dierentiation. Identi®cation of the molecules which interact with and function downstream of MLF1 will provide further insights into the details of MPM-MLF1/MLF1-mediated signaling pathways and the mechanisms of apoptotic induction.
The apoptosis-inducing domain contained in MLF1 seems quite unique, because it requires dimerization and nuclear transportation to induce cell death, whereas most of the well-known`death domains' function in the cytoplasm (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Adams and Cory, 1998) . NPM-MLF1-mediated apoptosis occurs with much slower kinetics than do other apoptotic inducers. In addition, the amino acid sequences in this Figure 4 Subcellular localization of NPM-MLF1 variants. NIH3T3 cells were transfected with expression vectors shown on the left of the panels, stained with anti-HA antibody after 3 days, and viewed by phase-contrast (PC) or¯uorescence (anti-HA) microscopy domain does not contain any known motifs and lacks signi®cant homology to previously identi®ed proteins. These results imply that NPM-MLF1 activates a novel signaling pathway of apoptotic induction. Deletion of N-terminal 83 amino acids, which are required for dimerization of NPM (Fujimoto et al., 1996; Bischof et al., 1997) , only partially impaired the apoptosisinducing activity of the fusion protein, while mutants lacking nuclear localization signal completely lost the ability. This can be explained by the fact that MLF1 itself has the ability to dimerize (N Yoneda-Kato, unpublished observation). Therefore, under the normal circumstances, MLF1 dimerization and subsequent activation of the protein may occur in a tightlyregulated manner, but fusion to NPM accelerates dimerization of the protein as well as transportation to the nucleus, leading to dysregulation of the MLF1 function.
The function of NPM-MLF1 is not restricted to induction of apoptosis, because co-expression of Bcl-2 suppressed apoptosis by NPM-MLF1 and gave proliferative advantages to cells, while Bcl-2 alone did not. Other apoptotic inducers such as c-Myc and E2F-1 also promote S phase entry (Evan et al., 1992; Askew et al., 1991; Wu and Levine, 1994; Qin et al., 1994; Shan and Lee, 1994) , but accelerated initiation of DNA replication itself does not trigger apoptotic pathways (Hsieh et al., 1997; Phillips et al., 1997) . For example, other E2F family members (E2F-2 and -3) induce S phase entry of serum-starved ®broblasts without evoking apoptosis (DeGregori et al., 1997) . Thus, NPM-MLF1 seem to activate at least two separate pathways; one transmits signals that ultimately reach the apoptotic eectors in the cytoplasm such as apoptotic Bcl-2-family members (Adams and Cory, 1998) and caspases (Thornberry and Lazebnik, 1998) , and the other may activate the cell cycle machinery to promote cell proliferation resulting in acquisition of growth advantages.
NPM-MLF1 does not seem to directly regulate the expression levels of Bcl-2 family of proteins; K562 cells transiently transfected with NPM-MLF1 contained equivalent levels of Bcl-2 and Bcl-xL compared with parental K562 cells and Bcl-2 protein levels remained unchanged in NIH3T3 cells in the presence or absence of ectopic NPM-MLF1 (unpublished observations). However, very rare survivors of K562 cells after NPM-MLF1 transfection expressed much higher levels of either Bcl-2 or Bcl-xL proteins (unpublished observations), indicating that enhanced anti-apoptotic signals can suppress NPM-MLF1-mediated cell death and collaboratively promote cell proliferation of the cells in a natural setting.
The t(3;5)(q25.1;q34) chromosomal translocation is restricted to MDS and AML (Raimondi et al., 1989) except for acute promyelocytic leukemia, which is a highly homologous subtype in AML speci®cally associated with translocation involving the RARa gene (Look, 1997) . These clinical observations indicate that the function of NPM-MLF1 is involved in development of MDS and/or progression from MDS to AML. The biological phenotype of NPM-MLF1 observed in this study may re¯ect some of the clinical features associated with the t(3;5) chromosomal translocation. Thus, in an in vivo setting, it is conceivable that production of the NPM-MLF1 fusion protein and activation of anti-apoptotic protooncoproteins (Bcl-2, Bcl-xL, and others) contributes to transformation into leukemia (Delia et al., 1992; Rajapaksa et al., 1996) by escaping the apoptotic phase, so-called ineective hematopoiesis characteristic of MDS (Clark and Lampert, 1990; McKenna and Cotter, 1997; Raza et al., 1995; Thompson, 1995; Yoshida, 1993) . However, an accumulation of additional molecular abnormalities may be required for completion of leukemic progression (Koeer, 1996; Fenaux et al., 1996; Gallagher et al., 1997) . Further investigation using NPM-MLF1-transgenic mice may provide a good model system with which to analyse the molecular basis of ineective hematopoiesis in MDS and multi-step progression from MDS to AML.
Materials and methods

Vector construction
cDNA fragments containing amino acid residues 1 ± 388, 1 ± 284, 1 ± 192, 193 ± 427, or 84 ± 427 of NPM-MLF1 fusion protein were excised by digestion with HindIII+AvaI, HindIII+StuI, HindIII+XmnI, XmnI+HindIII, and BsrGI +HindIII, respectively. Amino acids 84 ± 192 or 193 ± 284 were deleted by digestion with BsrGI+XmnI or with XmnI+StuI, respectively and ligated in frame using a SalI linker. The entire coding sequence of NPM, MLF1, or NPM-MLF1, and dierent regions of NPM-MLF1 cDNA were inserted into the expression vector (originally designed by Dr M Tanaka and modi®ed by Dr J Fujisawa), which contains a neo marker gene and can express HA-tagged exogenous cDNA driven by the CMV promoter.
Cell culture and transfections
K562 human leukemia cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS). Cells were electroporated with expression vectors and selected in medium containing 1 mg/ml of G418 (Geneticin; GIBCO) for 2 weeks (`Early Passage' cells) to remove cells which died by electronic shock or cells which did not uptake the input plasmids. By the end of this selection, the population of dead cells was less than 0.1% of the total culture. Transfected K562 cells were further maintained without G418 for an additional 2 months and used as`Late Passage' cells.
NIH3T3 mouse ®broblasts were passaged in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% FBS, and were transfected with expression vectors by the calcium phosphate-DNA precipitation method. Stable cell lines were obtained by culturing transfected cells in medium containing 1 mg/ml of G418 for 2 weeks. To induce apoptosis in NIH3T3 transfectants, cells were washed with PBS and incubated in medium containing 0.1% FBS for the times indicated. The cell viability was determined by morphology and a trypan blue exclusion assay. All biological assays were performed using transiently transfected cells as well as stable cell lines selected in G418 and identical results were obtained. In GFP experiments, more than 99% of GFP-positive cells expressed co-transfected proteins as determined by immuno¯uorescent staining.
Transient transfection of the plasmids into Cos7 cells were performed by electroporation as described previously (Yoneda-Kato et al., 1996) .
Protein analyses
Cells were lysed for 30 min on ice in EBC buer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 0.5% NP-40, and 1 mM EDTA) containing 5 mg/ml of aprotinin, 1 mM PMSF, 0.1 mM NaF, 0.1 mM NaVO 4 and 1 mM DTT. After clari®cation by centrifugation, lysates extracted from an equal number of cells were incubated with excess amounts of pre-immune rabbit serum or antiserum to C-terminal MLF1 amino acids (MLF1C) at 48C. After 1 h incubation with protein A-Sepharose beads, immunoprecipitates were collected by centrifugation and washed three times with icecold EBC buer. Immune complexes were separated on SDSpolyacryamide gels under reducing conditions, transferred to a PVDF membrane (Millipore), and immunoblotted with MLF1C as described (Yoneda-Kato et al., 1996) . Proteins were detected with the ECL blotting system (Amersham) according to the manufacturer's instructions.
To prepare direct lysates for immunoblotting, cells were lysed in SDS-sample buer (40 mM Tris-HCl, pH 6.8, 0.1 M DTT, 1% SDS, 10% glycerol, and 0.05% bromophenol blue) and boiled for 4 min. The cell lysates clari®ed by centrifugation were analysed by immunoblotting. Full-length NPM-MLF1 and wild-type MLF1 were detected using MLF1C. HA-and FLAG-tagged proteins were detected using mouse monoclonal antibody to HA and FLAG peptide epitopes, respectively (anti-HA antibody, Clone 12CA5; Boehringer Mannheim, anti-FLAG M5 antibody; Eastman Kodak). Anti-Bcl-2 antibody was purchased from Santa Cruz Biotechnology.
Immuno¯uorescence staining
Cells were ®xed in 3% paraformaldehyde, permeabilized in 0.5% Triton X-100, stained with MLF1C rabbit polyclonal, and anti-HA or anti-FLAG mouse monoclonal antibodies and incubated with¯uorescein (FITC)-linked antirabbit or antimouse IgG (Amersham). To detect proteins in GFPpositive cells, Texas Red-conjugated sheep antimouse or donkey antirabbit IgG (Amersham) was used as a secondary antibody. BrdU incorporation was determined using a 5-bromo-2'-deoxy-uridine labeling and detection kit (Boehringer Mannheim). PI staining and TUNEL assay were performed using an in situ apoptosis detection kit (Oncor) according to the manufacturer's instructions. The cell samples were viewed by phase-contrast or¯uorescence microscopy. More than 1000 cells were enumerated for each transfectant.
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